(Q40528468)

21 September 2017

title

A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer (English)

1 reference

21 September 2017

1 reference

Diane C Bodurka

2

0 references

Charles F. Levenback

7

object named as

Charles Levenback

1 reference

21 September 2017

6

Pedro T Ramirez

1 reference

21 September 2017

8

David M Gershenson

1 reference

21 September 2017

Judith K Wolf

1

1 reference

21 September 2017

Jacalyn B Gano

3

1 reference

21 September 2017

Michael Deavers

4

1 reference

21 September 2017

Lois Ramondetta

5

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

94

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

442-448

1 reference

21 September 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

p53 gene mutations and protein accumulation in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

7 January 2021

p53: puzzle and paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

p53; from inductive signal to cellular effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Suppression of human colorectal carcinoma cell growth by wild-type p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Adenovirus-based p53 gene therapy in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Gene therapy: adenovirus vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Comprehensive criteria for assessing therapy-induced toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Catheter complications associated with intraperitoneal chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Long-term access to the peritoneal cavity in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Adenoviral-mediated suicide gene therapy for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Why did p53 gene therapy fail in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.041

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.05.041

1 reference

21 September 2017

1 reference